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Abstract
Background: This work was carried out to assess the patterns and prevalence of resistance to
chloroquine (CQ) and sulphadoxine-pyrimethamine (SP) in Iran.
Methods: The prevalence of pfcrt K76T, pfmdr1 N86Y, pfdhfr N51I, C59R, S108N/T and I164L and
codons S436F/A, A437G, K540E, A581E, and A613S/T in pfdhps genes were genotyped by PCR/
RFLP methods in 206 Plasmodium falciparum isolates from Chabahar and Sarbaz districts in Sistan
and Baluchistan province, Iran, during 2003–2005.
Results: All P. falciparum isolates carried the 108N, while 98.5% parasite isolates carried the 59R
mutation. 98.5% of patients carried both 108N and 59R. The prevalence of pfdhps 437G mutation
was 17% (Chabahar) and 33% (Sarbaz) isolates. 20.4% of samples presented the pfdhfr 108N, 59R
with pfdhps 437G mutations. The frequency of allele pfcrt 76T was 98%, while 41.4% (Chabahar)
and 27.7% (Sarbaz) isolates carried pfmdr1 86Y allele. Eight distinct haplotypes were identified in all
206 samples, while the most prevalent haplotype was T76/N86/N51R59N108/A437 among both study
areas.
Conclusion: Finding the fixed level of CQ resistance polymorphisms (pfcrt 76T) suggests that CQ
must be withdrawn from the current treatment strategy in Iran, while SP may remain the treatment
of choice for uncomplicated malaria.
Background
Drug resistance is the most serious problem in achieving
control of malaria. The spread of Plasmodium falciparum
resistance to available cheap drugs, the increased cost of
insecticides, the vector's resistance to insecticides and the
lack of an effective vaccine, together with a socio-eco-
nomic instability in many malaria-endemic region,
impact on malaria control. Therefore, surveillance and
prevention of drug resistance and also effective curative
chemotherapy have become more important to be consid-
ered as the primary approach to malaria control. For dec-
ades, chloroquine (CQ) was an efficacious antimalarial,
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however malaria parasite resistance to treatment with
chloroquine has already complicated malaria manage-
ment and has been associated with increased malaria
morbidity and mortality [1,2]. The antimalarial com-
pounds sulphadoxine (S) and pyrimethamine (P) are usu-
ally given together as a synergistic combination, known
commercially as Fansidar® [3], and represent an effective
agent against chloroquine-resistant P. falciparum. How-
ever, resistance to this drug has also been reported from
parts of South East Asia, Latin America and Africa [4-6].
In Iran, malaria was a serious health problem in the past
and according to the records of Center for Diseases Man-
agement and Control (CDMC), Ministry of Health and
Medical Education (MHME), during the last decade
(1990–1999) the annual malaria cases have decreased
from 96,340 in 1991 to 24,000 in 2005. Malaria transmis-
sion mostly occurs in the south-eastern parts of the coun-
try in Sistan-Baluchistan, Hormozgan and Kerman
(mainly in Kahnoudj) provinces. Resistance of P. falci-
parum  to chloroquine has increased since it was first
reported in 1983 in Sistan-Baluchiatan province and later
in Hormozgan province in 1986 [7], and currently
accounts for more than 78.5% of treatment failures in
south-eastern provinces of Iran [8]. Resistance to SP was
confirmed in malaria-endemic areas of Iran by in vitro and
in vivo tests [9]. Despite the report of resistance to these
drugs in Iran, CQ and SP are still used as antimalarial
drugs in this region.
Plasmodium falciparum resistance to CQ and SP has been
associated with combinations of the presence of single
nucleotide polymorphisms (SNPs) in a number of P. fal-
ciparum genes. CQ resistance is associated with polymor-
phisms in the P. falciparum chloroquine resistance
transporter (pfcrt) gene [10-12], while polymorphisms in
the  P. falciparum multidrug resistance 1 (pfmdr1) gene
have been shown by transfection to modulate higher lev-
els of CQ resistance [13]. In this regards, K76T mutation
of the pfcrt gene is strongly associated with CQ resistance
[10], while N86Y mutation of pfmdr1 gene may modulate
its degree [14]. SP resistance is associated with polymor-
phisms in the dihydropteroate synthetase gene (dhps) and
the didydropolate reductase gene (dhfr) [15,16]. Among
SNPs currently identified, the N51I, C59R, I164L with
S108N/T in dhfr  confer increasing levels of pyrimeth-
amine resistance [17]. Similarly, polymorphisms at posi-
tions S436A/F, A437G, L540E, A581G and S613A/T in
dhps are the key mutations associated with sulphadoxine
resistance. The polymorphism 437G in dhps gene appears
to be selected first by drug pressure and accompany with
polymorphisms at other positions confers increasing lev-
els of resistance to this drug [18]. Several studies have
revealed that the differing degrees of antimalarial drug
resistance are dependent upon the number and combina-
tion of mutations present in aforementioned genes [19-
21]. Initial clinical failures to SP usually become evident
when an isolate carries a triple mutant, 51I, 59R and 108N
in the pfdhfr gene with or without additional mutations in
pfdhps [22-24], however, the quintuple mutant carrying all
of dhfr triple mutant at codons 51I, 59R and  108N also in
combination with double mutant at codons 437G and
540E in dhps  are associated with SP treatment failure
[20,24-27]. These SNPs could be used as rapid molecular
marker for detecting these mutations, therefore represent
molecular epidemiology surveillance tools of antimalarial
resistance, which may replace the conventional in vitro or
in vivo phenotyping assays [28,29].
The aim of the present study was to complement existing
data on molecular studies by determining the frequency
of known mutations in dhfr and dhps genes of P. falciparum
isolates from south-eastern region of Iran. In addition, we
investigated the possibility of an association between CQ
and SP resistance by analysing pfcrt and pfmdr1 mutations
on the same P. falciparum isolates. The data presented here
revealed the prevalence of mutations associated to CQ
and SP resistance in P. falciparum isolates collected at
health centers in Chabahar and Sarbaz districts in Sistan
and Baluchistan province, Iran and therefore, will be con-
tributed to the development of strategies for therapeutic
intervention of malaria in Iran.
Materials and methods
Study sites and samples collection
Chabahar and Sarbaz districts in Sistan and Baluchistan
province in south-eastern part of Iran have been selected
as study areas. Both areas are malaria endemic and the
patients have access to antimalarial drugs through local
health centers. In Chabahar district samples were col-
lected from Chabahar, Nowbandiyan and Dargas health
centers, however, in Sarbaz district most of the samples
were collected from Pishin health center (5 Km far from
border line with Pakistan), where, there is a lot of popula-
tion movement to Pakistan and vice versa (Figure 1). In
these regions, malaria transmission is year-round with
two peaks, the first in May to August with P. vivax as the
predominant species and the second peak from October
to November, when both P. falciparum and P. vivax infec-
tions are generally equally recorded. 206 blood samples
were collected from P. falciparum-infected patients, aged
from 1 to >60 years old with Iranian, Afghani and Paki-
stani nationals from Chabahar (n = 152) and Sarbaz (n =
54) districts in Sistan and Baluchistan during 2003 to
October 2005.
Thin and thick blood films were stained with Giemsa and
examined microscopically for detection of P. falciparum
parasite. Approximately 1 ml venous blood was obtained
in tube containing EDTA from patients who were con-Malaria Journal 2007, 6:148 http://www.malariajournal.com/content/6/1/148
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firmed to be positive for the presence of P. falciparum par-
asites. Then all patients were treated with CQ (25 mg/kg
body weight over 3 days) plus primaquine (P) (0.75 mg/
kg single dose in third day) as first line drug and if needed
treated with single dose of SP as second line drug for treat-
ment of uncomplicated malaria cases. Patients' or parents'
informed consent was obtained before inclusion in the
study. The study was reviewed by, and received Ethical
Clearance from Pasteur Institute of Iran. Blood samples
were collected in tube containing EDTA, stored at 4°C,
and then transported to the main laboratory in Tehran.
Parasite DNA extraction and nested polymerase chain 
reaction amplification of pfdhfr and pfdhps genes
The Parasite genomic DNA was extracted from infected
red blood cells using phenol/phenol-chloroform fol-
lowed by ethanol precipitation as described previously
[30]. Nested PCRs were performed for dhfr and dhps genes,
and all reactions were carried out in 25 μl reaction mix-
tures containing 1.5–3 mM MgCl2, 200 μM dNTP mixture
(invitrogene, USA), 1 unit of Taq polymerase (invitrogen,
USA), and a pair of primers (10 pmol each). For both dhfr
and dhps one to two microliters of DNA was used as tem-
plate in the first reaction and for second reaction, 1 μl of
first PCR product, if no band was seen from first round
PCR product, whereas 1 μl of a 1/100 dilution of the sam-
ples with an intense band was used as template for sec-
ondary PCR. The negative (water) controls were used in
all PCRs. The PCR primers and conditions for both genes
were those published by Duraisingh et al. [31]. Secondary
PCR products were resolved by electrophoresis on 1–2%
agarose gels and visualized by staining with ethidium bro-
mide.
Restriction Fragment Length Polymorphism-Polymerase 
Chain Reaction of pfdhfr and pfdhps genes
The mutation specific restriction endonuclease digestion
was used to detect SNPs in dhfr at positions N51I, C59R,
S108N/T, I164L, and in dhps at position S436F/A, A437G,
K540E, A581E, A613S/T [31]. A number of restriction
enzymes were used for RFLP of PCR products. For dhfr, the
PCR products were digested with TasI and TaqI to deter-
mine the polymorphisms at codons 51 and 59, respec-
tively. Three enzymes, AluI, BsrI, and MvaI were used to
identify wild and mutant dhfr allele at codon 108 and
DraI used to detect mutation at position I164L. For dhps,
the PCR products were digested with HhaI, MnlI and Hin-
dIII to determine the polymorphisms at codon 436, AvaII
and MwoI for codon 437, FokI, BstUI and MwoI to deter-
mine the polymorphisms at codons 540, 580 and 613,
respectively. Digestions were done in 20 μl reactions con-
taining 10 μl of PCR fragments according to the manufac-
turer's instructions (New England Biolab, Beverly, MA,
USA; Roche, Germany; Invitrogen, Carlsbad, CA).
Digested products were subjected to electrophoresis on
1.5–2% agarose or 2–3% Metaphor agarose gels, and vis-
ualized by ultraviolate (UV) transillumination.
Detection of pfcrt and pfmdr1 mutations by restriction 
digestion of PCR products
For mutation detection at codon K76T in pfcrt and N86Y
in pfmdr1 genes one to two microliters of DNA was used
as template in the first reaction (if no band was seen),
whereas 1 μl of a 1/100 to 1/500 dilution of the samples
with an intense band from first round PCR product was
used as template for the secondary PCR. The PCR primers
and conditions for both genes were those published pre-
viously [10,32]. Purified genomic DNA from P. falciparum
clones HB3 (Chloroquine sensitive) and Dd2 (chloro-
quine resistant) were used as positive controls, and water,
extracted uninfected blood used as negative controls. PCR
products were resolved by electrophoresis on 1–2% agar-
ose gels and visualized by staining with ethidium bro-
mide.
Following amplification of the fragments concerned, pol-
ymorphisms in the pfcrt and pfmdr1 genes were assessed
by the mutation specific restriction endonuclease diges-
tion to detect Single Nucleotide Polymorphisms (SNPs)
in pfcrt at positions K76T, and in pfmdr1 at position N86Y/
H [10,32]. A number of restriction enzymes were used for
RFLP of PCR products. For pfcrt, the PCR products were
digested with ApoI, determine the polymorphisms at
codons 76. For pfmdr1, three enzymes, ApoI, NsiI and
AFlIII were used to identify polymorphisms at codon 86.
Digestions were done in 20 μl reactions containing 10 μl
of PCR products according to the manufacturer's instruc-
tions (New England Biolab, Beverly, MA, USA; and/or Fer-
mentase, Vilnius, Lithuania; New England Biolabs,
Map of Iran indicating the location of the study area in  Chabahar and Sarbaz districts situated in the south-eastern  corner of Baluchistan Province, from where the P. falciparum  isolates were collected Figure 1
Map of Iran indicating the location of the study area in 
Chabahar and Sarbaz districts situated in the south-eastern 
corner of Baluchistan Province, from where the P. falciparum 
isolates were collected. S&B: Sistan and Baluchistan prov-
ince, Ch: Chabahar, P: PishinMalaria Journal 2007, 6:148 http://www.malariajournal.com/content/6/1/148
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Beverly, MA). If there was doubt about a complete diges-
tion, reactions were repeated overnight. Digested products
were subjected to electrophoresis on 1.5–2% agarose or
2–3% Metaphor agarose gels, and visualized by ultravio-
late (UV) transillumination.
Results
Pfdhfr and pfdhps genotypes
All 206 P. falciparum isolates were successfully genotyped
for the detection of dhfr and dhps mutations associated to
SP resistance. All P. falciparum isolates (100%) from both
Chabahar and Sarbaz districts were found to carry the
mutant type 108N, and 98.5% of them carried the 59R
mutation, however the 51I mutation was present in
0.97% of examined samples (Table 1). The majority of the
Patients (98.5%) were found to carry both 108N and 59R
in pure form, while retaining a wild-type mutation at
position 51 and 164 (Table 2).
In case of the dhps gene, polymorphisms in different loci
of dhps (S436F/A, A437G, K540E, A581E and A613S/T))
were investigated. All isolates were found to carry wild-
type amino acids at positions 436, 540, 581, and 613,
while 437G mutation in pur form was detected among
17% and 33% examined samples collected from Chaba-
har and Sarbaze districts, respectively (Table 1). Muta-
tions at codons 108N, 59R of pfdhfr with pfdhps 437G
were detected in 20.4% of examined samples (Table 2).
pfcrt K76T and pfmdr1 N86Y
The frequency of pure mutant of allele pfcrt 76T was 98%
in both Chabahar and Sarbaz districts (Table 1). The fre-
quency of the mutant pfmdr1 86Y allele was 41.4% and
27.7% among isolates from Chabahar and Sarbaz dis-
tricts, respectively (Table 1).
Distribution of pfcrt, pfmdr1, pfdhfr and pfdhps 
haplotypes in Iran
Combination of pfcrt, pfmdr1, pfdhfr and pfdhps haplotypes
among all 206 samples in this study demonstrated 8 dis-
tinct haplotypes (Figure 2). The two most prevalent hap-
lotypes among samples were T76/N86/N51R59N108/A437
(47%) and T76/Y86/N51R59N108/A437 (28.6%). In addition,
the majority of isolates from Chabahar (48%) and Sarbaz
(43%) were belonging to haplotype T76/N86/N51R59N108/
A437 (Figure 2). pfcrt 76T and pfmdr1 86Y with the pfdhfr
59R, 108N and pfdhps 437G mutations was detected in
10.7% isolates from Chabahar (n = 13) and Sarbaz (n = 9)
districts (Table 2).
Discussion
In Iran, chloroquine-resistant parasites were first observed
in 1983 [33] and later reported for more than 78.5% of
treatment failures in south-eastern provinces of Iran [8],
but it is still under use as antimalarial drugs in these
regions. In both Chabahar and Sarbaz districts pfcrt 76T
polymorphism was fixed in parasites populations, as
shown by the high rate of polymorphism and no mixed
alleles, however, lower frequency of pfmdr1 86Y polymor-
phism has been detected among Sarbaz isolates. Based on
the prevalence of pfcrt  76T (98%) and pfmdr1  86Y
(37.8%) in all 206 isolates, it could be concluded that
pfcrt76T but not pfmdr1 86Y mutation is strongly associ-
Table 1: Frequency distribution of mutations conferring resistance to chloroquine and pyrimethamine-sulphadoxine in Plasmodium 
falciparum isolates from southeastern Iran
Gene Codon Chabahar (n = 152) Sarbaz (n = 54)
Mutation (%) Mutation (%)
Choloroquine pfcrt 76T 149 (98%) 53 (98%)
pfmdr 1 86Y 63 (41.4%) 15 (27.7%)
86N/Y 1 (0.77%) 1 (1.96%)
Pyrimethamine pfdhfr 51I 1 (0.77%) 1 (1.96%)
59R 150 (98.6%) 53 (98%)
108N 152 (100%) 54 (100%)
108T --
164L --
Sulphadoxine pfdhps 436A --
436F --
437G 26 (17%) 18 (33%)
437A/G 3 (1.9%) 3 (5.5%)
540E --
581G --
613N --Malaria Journal 2007, 6:148 http://www.malariajournal.com/content/6/1/148
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ated with CQ resistance and has the potential as a molec-
ular predictor for CQ therapeutic treatment failure in Iran.
Furthermore, in vivo and in vitro study of clinical failures
with SP reported since 1993 [9,34], but in vivo resistance
of P. falciparum to SP is not yet common in malarious
endemic area with a high level of CQ resistance in Iran. To
investigate and complete molecular surveillance on SP
efficacy in Iran, 206 collected P. falciparum isolates during
2003 to October 2005, have been analyzed. At the time
that the present study initiated, SP was used for CQ treat-
ment failures, as treatment failure of SP was not frequent
in the region, at the end of this study, the CDMC and
MHME revised the standard treatment recommendations
for uncomplicated malaria to CQ plus SP as first line and
Co-Artem, as second line anti malarial drugs, respectively.
All 206 P. falciparum isolates examined in this study carry
pfdhfr 108N mutation (100%) with no evidence of clinical
failure of SP in patients. Although it has been postulated
that pfdhfr 108N mutation might be a good marker of clin-
ical SP resistance [35], but high prevalence of this muta-
tion in areas with low clinical failure to SP may be
associated with prior primaquine exposure [36] and this
could explain the fixed prevalence of this mutation
among our isolates. Further study is needed to clarify the
association of primaquine exposure and pfdhfr  108N
mutation rates.
It was also found that polymorphism in the pfdhps gene
were found less frequent in P. falciparum population in
Iran. The only mutation detected in P. falciparum isolates
from both study areas was pfdhps 437G. This mutation
was rather more prevalent in Sarbaz (33%), in border area
with Pakistan, while its prevalence in Chabahar isolates is
almost half (17%), indicating that this mutant parasites
might have been spread through the Indian subcontinent
to Pakistan and further to Iran. However, this observation
remains to be clarified by further study on Pakistani P. fal-
ciparum isolates. Also in comparison with our previous
work [37], the results of this study showed that the rate of
pfdhps  437G mutation has been increased from 17%
mixed form to 21.3% pure form in Iran. Similarly, Heidari
and co-workers [34] reported the increase of this mutation
in Sistan and Baluchistan province.
Chabahar and Sarbaz isolates showed similar mutations
pattern and combination at pfdhfr 51I, 59R, 108N and
pfdhps 437G positions, but with varied mutation preva-
lence. The haplotype 59R, 108N (pfdhfr), 437G (pfdhps)
was more prevalent in Sarbaz (35.3%) than Chabahar
(15.8%) districts. It is worth to note that, 27.4% of Sarbaz
isolates with these three mutations isolated from patients
who either had trip to or came from Pakistan two-three
weeks prior to blood sampling. Hence to control of the
disease, it should be kept in our mind the possibility of
the spread of these alleles from neighbouring countries to
malaria settings in Iran. Therefore, the predominant pfdhfr
haplotype in Iran seems to be N51,59R,108N rather than
51I,59R,108N. Low prevalence of triple mutation in
examined isolates in this study was similar with finding
from India [38,39], Sri Lanka [40] and Papua New Guinea
[41], however was different with Vietnam [16,42]; Malay-
sian [43], Gaboni [44] and Brazilian [45] isolates, where
the predominant haplotype was 51I,59R,108N. This may
suggested that the pfdhfr allele has evolved independently
due to drug pressure in geographically isolates regions of
the world. Regarding CQ resistant P. falciparum, it was
believed that resistant parasites emerged in South East
Asia and then spread to Africa via the Indian subconti-
nent; however the results of recent works [46,47] was con-
trary to such hypothesis. In case of SP resistant parasites,
if the same hypothesis was true, the data from present
study is not supporting a presumed spread of resistant
parasites from South East Asia, and multiple geographic
foci for the origin of both CQ and SP resistance mutations
might be postulated. The high prevalence of double muta-
tions at codon 59R/108N rather than 51I/108N in our
parasite isolates suggested that 51I mutation would be a
good molecular marker for the triple mutant and indicat-
ing failure to pyrimethamine in Iran and also Indian sub-
continent. In addition, these two mutations with the
mutation at 437G position in dhps indicate that the P. fal-
ciparum parasite populations have the potential to evolve
Table 2: The frequency distribution of SNPs combinations of pfcrt and pfmdr1 associated to chloroquine resistance, plus pfdhfr and 
pfdhps alleles associated with pyrimethamine-sulphadoxine resistance in clinical isolates of Plasmodium falciparum in southeastern Iran
Gene Codon/Mutation Chabahar Sarbaz Total
n = 152 n = 54 n = 206
pfcrt + pfmdr 1 76T + 86Y 63 (41.4%) 16 (29.6%) 79 (38.3%)
Pfdhfr 59R + 108N 150 (98.7%) 53 (98%) 203 (98.5%)
Pfdhfr 51I + 59R + 108N 1 (0.77%) 1 (1.96%) 2 (1.1%)
Pfdhfr + pfdhps 59R + 108N + 437G 24 (15.8%) 18 (35.3%) 42 (20.4%)
pfcrt + pfmdr 1 + pfdhfr 
+ pfdhps
76T + 86Y + 59R + 
108N +437G
13 (8.55%) 9 (17.6%) 22 (10.7%)Malaria Journal 2007, 6:148 http://www.malariajournal.com/content/6/1/148
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into dhfr/dhps quintuple mutant polymorphism in near
future, therefore, monitoring of the status of dhps alleles
could be a high priority as a predictor of developing clin-
ical resistance to sulphadoxine in this region.
Conclusion
In conclusion, the present results demonstrated the low
progressing rate in SNPs frequencies in both pfdhfr and
pfdhps genes since 2003 to 2005, more likely due to not
having easily access to SP as antimalarial drug for self
treatment by patients in these malaria-endemic areas of
Iran. In addition, finding the fixed level of CQ resistance
polymorphisms (pfcrt 76T) in our studied isolates sug-
gested that the CQ must be withdrawn from the current
treatment strategy in Iran. However, since October 2005,
based on evidence of high rates of chloroquine treatment
failure, Iran revised its national policy for treatment of
malaria and SP combination therapy with CQ have
Frequency distribution of the combination pfcrt/pfmdr1/pfdhfr/pfdhps haplotypes obtained from 206 isolates collected in Sistan  and Baluchistan of Iran Figure 2
Frequency distribution of the combination pfcrt/pfmdr1/pfdhfr/pfdhps haplotypes obtained from 206 isolates collected in Sistan 
and Baluchistan of Iran. The haplotype T76/N86/N51R59N108/A437 was the most prevalent among Chabahar (48%) and Sarbaz 
(43%) P. falciparum isolates. Mutated amino acids are boldfaced.
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replaced the CQ/P as first line antimalarial drug. Thus
now with more availability of SP there is possibility of
increasing resistance to SP from moderate to high and its
rapid spread in this particular malaria setting. Therefore,
although the results of this study suggested that SP may
remain the treatment of choice for uncomplicated malaria
in Iran, but due to high rates of treatment failures to CQ,
serious consideration must now be given to replace SP/
CQ combination therapy with SP/artemisinin as first line
antimalarial drugs in near future in Iran, which has
already been shown to be effective against CQ resistant
isolates of P. falciparum.
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